DRUGS MADE IN AMER ACQUTN CO

Historical 13F Holders

Symbol
DMAA
CUSIP
G2847J104
All holders as of
Q2 2026
Type
Equity
Class
ORD SHS
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G2847J104 since 12/18/2024, newest first.

Filer % of Class Filed
First Trust Capital Management L.P. 13G/A Amendment 1
3.2% 8/14/2026
Event 6/30/2026
Karpus Management, Inc. 13G/A Amendment 2 10.3% 8/14/2026
Event 6/30/2026
Mizuho Financial Group, Inc. 13G/A Amendment 1 8.5% 8/13/2026
Event 6/30/2026
Glazer Capital, LLC 13G/A Amendment 1
4.1% 8/13/2026
Event 6/30/2026
Feis Equities LLC 13G
5.1% 6/26/2026
Event 6/18/2026
Mizuho Financial Group, Inc. 13G 6.0% 5/14/2026
Event 3/31/2026
Hudson Bay Capital Management LP 13G/A Amendment 1
4.6% 11/12/2025
Event 9/30/2025
Karpus Management, Inc. 13G/A Amendment 1 8.2% 8/14/2025
Event 6/30/2025
First Trust Capital Management L.P. 13G
6.2% 5/15/2025
Event 3/31/2025
Polar Asset Management Partners Inc. 13G 5.7% 5/15/2025
Event 3/31/2025
Glazer Capital, LLC 13G
5.4% 5/15/2025
Event 3/31/2025
Hudson Bay Capital Management LP 13G
5.4% 5/14/2025
Event 3/31/2025
Karpus Management, Inc. 13G 6.9% 5/14/2025
Event 3/31/2025
Drugs Made In America Acquisition LLC 13D
12.5% 3/3/2025
Event 2/18/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 24 14.0 M $146 M
2026 Q1 39 22.9 M $237 M
2025 Q4 39 22.6 M $232 M
2025 Q3 39 22.5 M $231 M
2025 Q2 33 22.0 M $224 M
2025 Q1 26 19.7 M $171 M